Gets approval for restricted emergency use
New Delhi, Jun 29: The Drugs Controller General of India (DCGI) has granted permission to Cipla to import Moderna’s COVID-19 vaccine for restricted emergency use in the country as per the provisions of the New Drugs and Clinical Trial Rules, 2019 under Drugs and Cosmetics Act, 1940. Any new drug to enter the domestic Indian market needs this approval. Moderna’s mRNA vaccine, developed in the United States, will be the fourth COVID-19 jab to be available in India, others being Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin, and Russia’s Sputnik V. Moderna vaccine is a two-dose system given four weeks apart. On June 1st , the Central government had eased out rules for entry of vaccines approved by international drug regulators like US FDA, UK’s MHRA, Japan’s PMDA, or WHO. DCGI decided to waive testing of batches at Central Drugs Laboratory (CDL).
